Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
$1000 Invested In Seagen 15 Years Ago Would Be Worth This Much Today ↗
Seagen (NASDAQ:SGEN) has outperformed the market over the past 15 years by 14.65% on an annualized basis producing an average annual return of 21.09%. Currently, Seagen has a market capitalization of... 
Via Benzinga
News headline image
Why Merck's Rumored $40 Billion Seagen Buyout Is On Shaky Ground ↗
The deal is expected to cost Merck roughly $40 billion. 
Via Investor's Business Daily
News headline image
This Favorable Sign Appears On Seagen's Chart ↗
If history is any guide, there may be good fortune ahead for shares of Seagen (NASDAQ:SGEN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
News headline image
Check Out What Whales Are Doing With SGEN ↗
A whale with a lot of money to spend has taken a noticeably bullish stance on Seagen. Looking at options history for Seagen (NASDAQ:SGEN) we detected 10 strange trades. 
Via Benzinga
News headline image
Where Seagen Stands With Analysts ↗
Seagen (NASDAQ:SGEN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
From Seagen Inc.
Via Business Wire
News headline image
This Analyst Believes Seagen Is Evaluating Strategic Alternatives ↗
 
Via Benzinga
News headline image
Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ ↗
 
Via Benzinga
News headline image
Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech? ↗
Two major cancer players are reportedly closing in on a massive merger. 
Via Investor's Business Daily
News headline image
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
News headline image
Seagen (SGEN) Stock Pops on Merck Buyout Rumors ↗
Seagen (SGEN) stock is getting a boost on Thursday as rumors circulate that Merck (MRK) is considering a buyout of the biotechnology company. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Merck Is Sending Seagen Stock Higher Today ↗
Seagen Inc (NASDAQ: SGEN) shares are trading higher Thursday following reports suggesting Merck & Company Inc (NYSE: MRK) is in advanced talks to acquire the company. 
Via Benzinga
News headline image
Where Seagen Stands With Analysts ↗
Analysts have provided the following ratings for Seagen (NASDAQ:SGEN) within the last quarter: 
Via Benzinga
News headline image
Benzinga Before The Bell: Elon Musk's Kids, Apple's Potential Security Measure, Covid-19 Vaccine Wastage And Other Top Financial Stories Thursday, July 7 ↗
CNBC 
Via Benzinga
News headline image
Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks: Report ↗
 
Via Benzinga
News headline image
5 Best And Worst Performing Large-Cap Stocks In June 2022 ↗
Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Seagen's Tucatinib/Trastuzumab Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer Patients ↗
 
Via Benzinga
News headline image
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,400 Today ↗
Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 18.41% on an annualized basis producing an average annual return of 27.81%. Currently, Seagen has a market capitalization of... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Seagen Surges As Merck Takeover Deal Reportedly Accelerating ↗
The news comes after ex-CEO Clay Siegall was arrested on domestic violence charges. 
Via Investor's Business Daily
News headline image
Benzinga Before The Bell: Gun Safety Bill. Bill Gates's North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24 ↗
Reuters 
Via Benzinga
News headline image
SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know ↗
SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). 
Via Benzinga
News headline image
SGEN Stock Alert: Is Merck About to Buy Seagen? ↗
Today, various reports have highlighted a potential deal for Merck to buy out Seagen, taking SGEN stock on a nice ride this afternoon. 
Via InvestorPlace
News headline image
89 Biggest Movers From Friday ↗
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
33 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.